



## ASX ANNOUNCEMENT

### Lumos Announces Intention to Undertake Entitlement Offer

**MELBOURNE, Australia (3 September 2024)** – Lumos Diagnostics Holdings Limited (ACN 630 476 970) (ASX: LDX) (**Lumos** or **Company**) is pleased to announce that it intends to undertake a pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**), to raise up to approximately A\$10.0 million (before costs) at a price of A\$0.038 (3.8 cents) per fully paid ordinary share (**Share**), on the basis of 1 new Share for every 1.82 Shares held as at 7.00pm (Sydney time) on the record date (**Record Date**).

The offer price of A\$0.038 per Share represents a 17.4% discount to the last closing Share price of \$0.046 (as at 3 September 2024) and a 12.0% discount to the 5-day VWAP of \$0.0432 (as at 3 September 2024).

New Shares issued under the Entitlement Offer will rank equally with the existing Shares on issue.

The Entitlement Offer will provide eligible shareholders with the opportunity to take up new Shares proportional to their shareholding and mitigate the effect of dilution. Eligible shareholders who do not take up their entitlement under the Entitlement Offer in full or in part will not receive any value in respect to those entitlements not taken up.

#### Use of Funds

Funds raised from the Entitlement Offer are intended to be applied towards:

- (a) completion of the FebriDx Clinical Laboratory Improvement Amendment (CLIA) waiver trial in the US, product development, sales & marketing activities;
- (b) general working capital; and
- (c) costs of the Entitlement Offer.

#### Appointment of Lead Manager

The Entitlement Offer is to be lead managed by Bell Potter Securities Limited.

## Indicative Timetable

An indicative timetable in respect of the Entitlement Offer is set out as follows:

Event <sup>1</sup>	Sydney, Australia time
Trading Halt	Wednesday, 4 September 2024
Announcement of the Offer	Wednesday, 4 September 2024
Institutional Entitlement Offer Opens	Wednesday, 4 September 2024
Announcement of results of Institutional Entitlement Offer and trading halt lifted	Friday, 6 September 2024
Record Date for Entitlement Offer	7:00pm Friday, 6 September 2024
Settlement of Institutional Entitlement Offer	Wednesday, 11 September 2024
Retail Entitlement Offer opens and Retail Offer Booklet made available	Wednesday, 11 September 2024
Issue of New Shares under the Institutional Entitlement Offer	Thursday 12 September 2024
Retail Entitlement Offer closes	Friday, 2 October 2024
Results of the Retail Entitlement Offer announced	Tuesday 8 October 2024
Settlement of Retail Entitlement Offer	Tuesday 8 October 2024
Allotment of Retail Entitlement Offer Securities	Wednesday, 9 October 2024
Commencement of trading of New Shares issued under the Retail Entitlement Offer	Thursday, 10 October 2024

<sup>1</sup>The above timetable is indicative only and subject to change without notice in accordance with the ASX Listing Rules and *Corporations Act 2001* (Cth).

The Company advises that further details are expected to be released on Wednesday, 4 September 2024.

**This announcement was approved by the Lumos Board of Directors.**

- Ends -

## About Lumos Diagnostics

*Lumos Diagnostics specialises in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

## Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### Media Contacts:

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

### Investor Contact:

Jane Lowe

Managing Director, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 117 774

### Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598

## Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.